



**William V. Williams, MD, FACP**  
**President & CEO, Director**

- Former VP, Exploratory Development, Incyte
- Former VP, Experimental Medicine, GlaxoSmithKline
- 11 drug approvals




**Jamieson Bondarenko, CFA, CMT**  
**Chairman of the Board**

- Former Managing Director, Equity Capital Markets, Eight Capital
- Former Managing Director, Dundee Securities Ltd.

## WHO WE ARE?

- A clinical stage immunotherapy company driven to fight cancer and improve patients' lives
- Lead asset Bria-IMT™ boosts the ability of the body's own cancer-fighting cells to destroy cancer
- **Ongoing pivotal Phase 3 registration study** in breast cancer under FDA Fast Track Designation
  - Advanced metastatic breast cancer causes over **40,000 deaths per year** in the U.S.
- Safety & efficacy data similar or superior to other approved breast cancer drugs when at a comparable stage of development
- Single agent and combination check point inhibitor (+ CPI) activity
  - Activity in CPI and antibody-drug conjugate (ADC) resistant patients
  - Activity in patients with CNS metastases
- Experience team involved with 19 approvals



### WHAT WE DO?

1. Express tumor antigens and GM-CSF to activate specific cancer fighting CD4+ and CD8+ T cells
2. Directly stimulate the immune system to enhance targeted killing of cancer cells

## WHY WE COMBINE WITH CHECK POINT INHIBITORS (CPI)

- Check point molecules are **"BAD"** → they block our immune cells from attacking cancer cells
- Check Point inhibitors (CPI) are **"GOOD"** → they overcome the cancer cells resistance to our immune systems
- Bria-IMT™ activates the immune system and together with CPI puts it in overdrive to fight cancer



## HOW ARE PATIENTS RESPONDING?

**Safety & efficacy data similar or superior to approved breast cancer drugs when at a comparable stage of development**

- Total of 54 enrolled
  - 11 patients in combination with pembrolizumab
  - 44 patients in combination with retifanlimab, (one patient cross over from pembrolizumab to retifanlimab)
- Overall survival (OS) of 13.4 months with Bria-IMT™ + CPI vs OS in similar metastatic breast cancer patients who have failed 2+ prior therapy attempts is 6.7-9.8 months\*
- Similar response seen in patients resistant to ADCs and CPIs
- 32 of 42 patients with available data and treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen
- No dose limiting toxicities to date
- Immune system activation and remarkable responses in CNS metastases

### Bria-IMT™ + CPI TURNS "COLD" TUMORS "HOT" i.e. IMMUNE SYSTEM ACTIVATION


**Baseline:**  
**Cold Tumor**




**After Three Cycles:**  
**Tumor Now Hot**

## REMARKABLE RESPONDERS HIGHLIGHTED

Baseline Scans




Six months  
On Treatment Scans




- Patient failed 13 prior treatment regimens
- Tumor behind the left eye causing proptosis (eye bulging) completely resolved

Pre-treatment



Post-treatment



- Patient failed 7 prior regimens including ADC Enhertu®
- Extensive proptosis remarkably improved
- Significant tumor reduction along with improvement in eye pain after only 3 cycles of treatment

## WHAT DOES THE FDA THINK?



- Interim analysis 2H2025 for possible early BLA filing 2026
- Survival-related end points for pivotal study
- Single registrational study for commercialization
- IND for next generation Bria-OTS™ cleared

## WHAT'S NEXT?

- Expand clinical sites and continue enrollment in pivotal Phase 3 registration study
- Ongoing phase 2 patient data updates through 2024
- Bria-OTS™ (*personalized off-the-shelf approach*) platform technology clinical trial commencement →
  - **BriaCell** immunotherapy appears to be most effective when patients match the Bria-IMT HLA-type
  - **Bria-OTS™** developed to match the patient's HLA-type. Simple saliva test to determine patients' HLA-type
  - Designed to provide HLA matched therapy to >99% of patients with advanced breast cancer in 4 cell lines
  - Developed into a **platform technology to provide personalized off-the-shelf immunotherapies for many cancers**



### Forward Looking Statements

#### BriaCell Therapeutics Corp. ("BriaCell")

This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of BriaCell Therapeutics Corp. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Company makes certain filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission (the "SEC"), all of which are available under our profiles on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov](http://www.sec.gov). For a more complete discussion of the risk factors affecting our business, please refer to these filings.

Our public communications, including this presentation, and SEDAR and SEC filings, may contain statements related to future, not past, events. These forward-looking statements are based upon current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as "believes," "estimates," "anticipates," "targets," "expects," "plans," "projects," "intends," "predicts," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

These forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our reliance on third parties to carry out a large portion of our business; the possibility that pre-clinical and initial clinical trials will not necessarily be predictive of future results; our ability to obtain additional capital to continue our operations; our reliance on key personnel; our success in completing the development of our products, commercializing our products or generating significant revenues; our ability to successfully develop, maintain and protect our proprietary products and technologies; and potential difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of visiting or traveling to our clinical trial sites because of the outbreak of COVID-19.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this presentation.